HCA Healthcare stock faces flat 2027 earnings amid payer pressure

HCA Healthcare is entering 2027 with resilient demand but limited earnings momentum. During its third-quarter earnings call on October 27, management said earnings next year should be generally consistent with 2026, while full guidance will follow with the January update. Becker's Hospital Review reported the outlook in a report published on October 27.

HCA Healthcare stock traded at 451.80 euros on Lang & Schwarz at 13:15 CET on Wednesday, November 11, 2026.

Volume growth meets weaker reimbursement

Management expects service volume to grow by 2% to 3% in 2027. That demand outlook is supported by steady patient needs, but the financial benefit is being reduced by a less favorable payer mix as some patients lose coverage through insurance exchanges and move into uninsured care.

Uninsured patients accounted for 10.5% of equivalent admissions in the third quarter, up from 8.5% a year earlier. Exchange-equivalent admissions fell 19% year over year, although they increased 8% from the second quarter. HCA estimated that the shift toward uninsured care reduced income before income taxes by 400 million US dollars in the quarter.

The company expects fewer people to lose exchange coverage in 2027 than in 2026, but still sees a meaningful effect on its payer mix. Management also said patients losing exchange coverage have been moving into uninsured status at a rate close to one for one, leaving patient volume growth unable to fully offset weaker reimbursement economics.

Medicaid payments add a headwind

HCA expects 550 million to 650 million US dollars less in Medicaid supplemental payment net benefits in 2027. The comparison is affected by several state programs that received grandfathered approvals in 2026 and paid HCA for services delivered in prior periods. Those benefits will not recur at the same level next year.

In the third quarter of 2026, revenue rose to 19.8 billion US dollars from 19.2 billion US dollars a year earlier, while net income declined to 1.58 billion US dollars from 1.64 billion US dollars. Operating income was 2.4 billion US dollars and the operating margin narrowed to 11.9% from 12.6%, according to Becker's Hospital Review.

Management expects its enterprise-wide resiliency program to improve cost performance. It also pointed to digital transformation, expanded shared services and strategic initiatives as potential offsets. The longer-term growth path depends on the exchange-related payer pressure easing, no material policy changes beyond HR 1 and those initiatives generating significant value.

January guidance is the next catalyst

The January earnings update will give investors a fuller view of 2027 revenue, earnings and reimbursement assumptions. Until then, enrollment results, Medicaid implementation and evidence of cost savings will shape expectations for whether HCA can convert resilient demand into renewed profit growth.

The broader US equity market provides the wider backdrop for HCA Healthcare stock.

More reporting on the outlook is available in Becker's Hospital Review. More news and analyses on HCA Healthcare stock are available on the company topic page.